论文部分内容阅读
目的探讨吡柔比星膀胱内灌注化疗对膀胱癌术后复发的防治效果及安全性。方法 48例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术(39例)或膀胱部分切除术(9例)。术后病理均证实为膀胱移行细胞癌,术后均定期给予吡柔比星经导尿管膀胱内灌注化疗,观察患者的治疗效果。结果 48例患者随访时间为6~24(12.5±6.3)个月,复发率为14.6%,多为1年内复发,复发病例均行再次手术治疗;主要不良反应为尿频、尿痛、尿急等膀胱刺激症状(5例)及肉眼血尿(3例),未经处理或对症处理后缓解。无肝肾功能损害等严重不良反应。结论膀胱内灌注吡柔比星对膀胱癌术后复发有良好的防治效果,且耐受性好、不良反应少。
Objective To investigate the efficacy and safety of intravesical instillation of pirarubicin in the treatment of postoperative recurrence of bladder cancer. Methods Forty-eight patients with superficial bladder cancer underwent transurethral resection of the bladder tumor (39 cases) or partial resection of the bladder (9 cases). Postoperative pathology were confirmed as bladder transitional cell carcinoma, postoperative were regularly given intravesical instillation of pirarubicin catheter chemotherapy to observe the therapeutic effect of the patients. Results 48 patients were followed up for 6 to 24 months (12.5 ± 6.3) months, the recurrence rate was 14.6%, mostly in 1 year recurrence, recurrence of patients underwent reoperation; the main adverse reactions were pollakiuria, dysuria, urinary urgency Bladder irritation (5 cases) and gross hematuria (3 cases) were relieved without treatment or symptomatic treatment. No serious adverse reactions such as liver and kidney dysfunction. Conclusion Intravesical injection of pirarubicin has a good preventive and therapeutic effect on postoperative recurrence of bladder cancer with good tolerability and few adverse reactions.